UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 8-K
____________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): February 29, 2012
____________________
BIOMIMETIC THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
____________________
| Delaware | 000-51934 | 62-1786244 |
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
389 Nichol Mill Lane, Franklin, Tennessee 37067
(Address of Principal Executive Offices) (Zip Code)
(615) 844-1280
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 29, 2012, the Board of Directors of BioMimetic Therapeutics, Inc. (the “Company”), on the recommendation of its Compensation Committee, approved a one-time cash incentive program for Russ Pagano, the Company’s Vice President, Clinical and Regulatory Affairs. Under the program, Dr. Pagano is eligible to receive cash payments of up to $100,000 upon the achievement of certain regulatory milestones.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIOMIMETIC THERAPEUTICS, INC. | ||
| By: | /s/ Earl Douglas | |
| Name: Earl Douglas Title: General Counsel | ||
Date: March 5, 2012